Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.55 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | ADH5 | P11766 | 1/20 | 0.45 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31658246 | 0.89 | AKR1C3 (0.61) | AKR1C3AKR1C2RARBNR1H4ADH5 | |
| SCHEMBL1890376 | 0.88 | GRIK1 (0.52) | AKR1C3AKR1C2NR1H4DCLRE1BNR4A1 | |
| SCHEMBL594843 | 0.88 | AKR1C3 (0.62) | AKR1C3AKR1C2NR1H4GAAMRGPRX4 | |
| SCHEMBL6252539 | 0.87 | AKR1C3 (0.68) | AKR1C3AKR1C2RARBNR1H4ADH5 | |
| SCHEMBL505879 | 0.84 | AKR1C3 (0.56) | AKR1C3AKR1C2RARBADH5DCLRE1B | |
| SCHEMBL122524 | 0.84 | CNR2 (0.57) | AKR1C3AKR1C2RARBNR1H4ADH5 | |
| SCHEMBL29707122 | 0.83 | ESR2 (0.58) | AKR1C3AKR1C2RARBNR1H4ADH5 | |
| SCHEMBL121338 | 0.83 | ESR2 (0.58) | AKR1C3AKR1C2RARBNR1H4ADH5 | |
| SCHEMBL6564874 | 0.83 | AKR1C3 (0.56) | AKR1C3AKR1C2RARBNR1H4ADH5 | |
| SCHEMBL2943490 | 0.82 | BCL2L1 (0.58) | AKR1C3AKR1C2RARBADH5NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9946847-B2 | Libraries of compounds having desired properties and methods for making and using them | BIOBLOCKS INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9946847-B2 | Libraries of compounds having desired properties and methods for making and using them | BIOBLOCKS INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20150269356-A1 | LIBRARIES OF COMPOUNDS HAVING DESIRED PROPERTIES AND METHODS FOR MAKING AND USING THEM | BIOBLOCKS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150269356-A1 | LIBRARIES OF COMPOUNDS HAVING DESIRED PROPERTIES AND METHODS FOR MAKING AND USING THEM | BIOBLOCKS INC (US) | 2015-09-24 | — | — | US | disclosed |
| WO-2014047463-A2 | LIBRARIES OF COMPOUNDS HAVING DESIRED PROPERTIES AND METHODS FOR MAKING AND USING THEM | BIOBLOCKS, INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2124565-A2 | N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| WO-2008089052-A2 | N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | AKR1C3 184/4885AKR1C2 190/4885RARB 1520/4885 |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | S1PR1, S1PR2, S1PR5 | AKR1C3 1902/4885AKR1C2 2495/4885RARB 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.